SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Bitcoin & Crypto Movers
Receive our Bitcoin / Cryptocurrency Reports, Free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
MDCOThe Medicines Co.
-0.05%84.0320.1%$614.99m
AMRNAmarin Corp. Plc
0.13%22.841.7%$318.94m
VRXValeant Pharmaceuticals International, Inc.
6.63%31.2814.1%$184.06m
ARQLArQule, Inc.
-0.97%20.010.6%$136.94m
SAGESAGE Therapeutics, Inc.
2.94%70.698.6%$121.05m
BHCBausch Health Cos., Inc.
6.63%31.280.0%$115.60m
ICPTIntercept Pharmaceuticals, Inc.
-3.23%115.5116.9%$91.79m
JAZZJazz Pharmaceuticals Plc
0.65%149.092.3%$91.14m
GWPHGW Pharmaceuticals Plc
2.99%105.966.2%$85.08m
PRGOPerrigo Co. Plc
0.95%54.326.8%$65.40m
AXSMAxsome Therapeutics, Inc.
2.31%49.182.0%$60.85m
HZNPHorizon Therapeutics Plc
2.36%33.016.6%$43.86m
ICLRICON plc
-0.17%161.464.2%$43.09m
UTHRUnited Therapeutics Corp.
0.34%92.8014.3%$35.89m
ENDPEndo International Plc
7.06%4.708.8%$33.53m

Company Profile

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.